7 results about "Antigen binding site" patented technology

The present application relates to a kind of multispecific and / or multivalent binding protein for preventing and / or treating HIV infection, it includes at least 3 antigen binding sites, part of antigen binding site is specifically bound HIV-1-gp41 or HIV-1-gp120 or HIV-1-gp160, still part of antigen binding site is specifically bound human CD4 receptor or human CCR5 receptor;The binding protein of the present application has excellent broad-spectrum neutralizing ability in the treatment or prevention of HIV infection, provides a new solution for the problem of drug resistance escape caused by HIV virus variation, in addition, the present application inventor also unexpectedly found that the binding protein of the present application can treat or prevent the tumor-related disease caused by HIV infection.

The present invention includes proteins, nucleic acids and methods of making and using an activatable antibody (aAb) comprising, in order, the following structure: a first light chain comprising: a first variable light region; a cleavable linker; a first heavy chain comprising: a first variable heavy region; wherein the cleavable linker prevents or reduces the first light chain and the first heavy chain from forming a first antigen binding site against a first antigen; and wherein cleavage of the cleavable linker releases the first heavy chain to allow formation of the first antigen binding site to bind a first antigen.

The invention provides a bispecific antibody aiming at IL6R (Interleukin-6 Receptor) and TNF (Tumor Necrosis Factor) alpha and application of the bispecific antibody. The bispecific antibody comprises a first structural domain and a second structural domain, wherein the first structural domain is specifically combined with an interleukin-6 receptor IL-6R, and the second structural domain is specifically combined with a tumor necrosis factor-alpha. Compared with a monoclonal antibody, the double antibodies have the advantages that a specific antigen binding site is added, so that the specificity is higher, tumor cells can be targeted more accurately, adverse reactions caused by off-target toxicity are reduced, a special function is exerted, biological functions which are difficult to achieve by monoclonal antibody drugs are achieved, and compared with a monoclonal antibody combination therapy, the treatment cost can be effectively reduced, and the treatment effect is better. The upper limit of the curative effect on autoimmune diseases such as rheumatoid arthritis at present is broken through.

The invention relates to the field of therapeutic antibodies for the treatment of a subject with castration-resistant prostate cancer. More in particular it relates to treating castration-resistant prostate cancer using a bispecific antibody that comprises an antigen binding site that can bind an extracellular part of ERBB2 and an antigen binding site that can bind an extracellular part of ERBB3. Also, it relates to treating castration-resistant prostate cancer using an antibody that comprises an antigen binding site that can bind an extracellular part of ERBB3. The invention also relates to treating castration-resistant prostate cancer using a combination of one of said antibodies and an androgen receptor axis-targeting agent.

Provided herein are methods for making epitope-targeted, conditionally activated pro-antibodies comprising: complementarity determining regions (CDRs) from an antibody identified from an in vivo, in vitro, or in silico antibody library; and one or more engineered epitope masks linked to a linker, wherein the linker comprises a peptide, polymer, or chemical linker that can be cleaved in vivo at a target site by an enzyme or chemically, and wherein the one or more engineered epitope masks bind to an epitope-specific antibody at a CDR of the epitope-specific antibody; and the one or more engineered epitope masks are linked to the antibody via the linker, wherein the mask is conditionally bound to the CDR of the epitope-specific antibody, and wherein cleavage of the linker releases the one or more engineered epitope masks from the antigen binding site.